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The homeo domain of the Oct-1 transcription factor directs formation of a muhiprotein-DNA complex 
containing Oct-l, the herpes simplex virus (HSV) trans-activator VP16, and a second host cell factor (HCF). 
This VP16-induced complex alters the regulatory activity of Oct-l, in part, by associating it with the potent 
VP16 acidic transcriptional activation domain. Here, we show that in the absence of HCF, VP16 can recognize 
specifically the Oct-1 homeo domain. A region of VP16 near the acidic activation domain appears to be 
involved exclusively in homeo domain recognition because a 4-amino-acid insertion within this region only 
affects the ability of VP16 to interact with Oct-l, leaving its DNA- and HCF-binding activities unchanged. A 
33-amino-acid peptide containing this region complexes with the Oct-1 POU domain bound to DNA, 
suggesting that this VP16 region contains an autonomous homeo domain recognition subdomain. 
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Homeo domain proteins are important regulators of gene 
transcription during development, but the mechanisms 
by which they control transcription are only beginning 
to be understood in detail (for review, see Hayashi and 
Scott 1990). The homeo domain is a tri-~-helical DNA- 
binding domain, similar in structure to the helix-turn- 
helix motif of prokaryotic repressor proteins such as h 
repressor (Qian et al. 1989; Kissinger et al. 1990). It has 
frequently been observed that homeo domains exhibit 
overlapping DNA-binding specificities in vitro that ap- 
pear inconsistent with the highly specific effects con- 
ferred by homeo domain proteins in vivo. Nonetheless, 
in Drosophila embryos, the homeo domain, rather than 
flanking protein regions, is largely responsible for pro- 
moter selectivity (Kuziora and McGinnis 1989; Gibson 
et al. 1990; Malicki et al. 1990; Mann and Hogness 1990; 
McGinnis et al. 1990). These observations suggest either 
that subtle differences in DNA-binding specificities are 
sufficient o produce strong promoter selectivity in vivo 
or that protein-protein i teractions involving homeo do- 
mains introduce additional binding or activation speci- 
ficities. 
Properties of the DNA-binding domains of both h re- 
pressor and the human homeo domain protein Oct-1 
(also referred to as OTF-1 and NFIII) show that the helix- 
turn-helix motif and the homeo domain can indeed par- 
ticipate in selective protein-protein i teractions that 
regulate transcription. The helix-turn-helix motif of 
repressor, in addition to binding DNA, is responsible for 
activating transcription from the phage promoter PRM" 
Amino acids within the helix-turn-helix motif involved 
in transcriptional ctivation do not appear to interact 
with DNA (Guarente t al. 1982; Hochschild et al. 1983); 
instead, they are thought to activate transcription by 
contacting RNA polymerase (Hawley and McClure 
1983). The site of interaction within RNA polymerase, 
however, is not known. Amino acids in the Oct-1 homeo 
domain that are not directly involved in DNA binding 
similarly regulate transcription, as they direct formation 
of a multiprotein-DNA complex containing the herpes 
simplex virus (HSV) protein VP16 (Stem et al. 1989}. 
This complex, which has been termed the VP16-induced 
complex, activates HSV immediate-early {IE) gene tran- 
scription (for review, see Goding and O'Hare 19891; but 
as is the case with the h repressor helix-turn-helix mo- 
tif, the protein target of the Oct-1 homeo domain in 
these interactions has not been identified. 
VP16 (also referred to as Vmw65 and ~-TIF) is a com- 
ponent of the HSV virion (Batterson and Roizman 1983; 
Campbell et al. 1984). Upon infection of the host cell, 
VP16 forms the VPl6-induced complex on TAATGA- 
RAT sequence lements in the IE gene promoters of HSV 
(McKnight et al. 1987; O'Hare and Goding 1988; Preston 
et al. 1988). In addition to VP16, this complex contains 
Oct-1 and a second less well-characterized host cell fac- 
tor, which we refer to as HCF (Gerster and Roeder 1988; 
apRhys et al. 1989; Kristie et al. 1989; Katan et al. 1990; 
Xiao and Capone 1990; also referred to as C1, VCAF, and 
CFF). VP16 contains apotent carboxy-terminal acidic ac- 
tivation domain (Sadowski et al. 1988; Triezenberg et al. 
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1988; Cousens et al. 1989) that, although not required to 
form the VPl6-induced complex (Greaves and O'Hare 
1989; Kristie et al. 1989; Werstuck and Capone 1989b), 
strongly activates HSV IE and related promoters (O'Hare 
and Goding 1988; Tanaka et al. 1988; Triezenberg et al. 
1988). Because Oct-1 does not readily activate these 
mRNA-type promoters in the absence of VP16 (Tanaka 
et al. 1988), VP16 acts as a transcriptional daptor that 
alters the promoter selectivity of Oct-l, allowing it to 
stimulate a new set of promoters. 
The TAATGARAT elements of HSV are frequently 
overlapped by sequences with similarity to the octamer 
motif (Pruijn et al. 1986; apRhys et al. 1989), yielding the 
sequence ATGCTAATGARAT (octamer underlined), 
which we refer to as an (OCTA+)TAATGARAT se- 
quence. The octamer motif is recognized by Oct-l, a 
member of the POU class of homeo domain proteins, 
which also includes the B-cell transcription factor Oct-2 
(OTF2) and the pituitary factor Pit-1 (GHF-1) (Herr et al. 
1988). POU-class transcription factors contain a highly 
conserved 160-amino-acid bipartite DNA-binding do- 
main composed of a carboxy-terminal homeo domain 
and an amino-terminal POU-specific region (Herr et al. 
1988; Sturm and Herr 1988). The POU domains of Oct-1 
and Oct-2 are closely related (Clerc et al. 1988; Sturm et 
al. 1988) and exhibit very similar, if not identical, DNA- 
binding specificities (Staudt et al. 1986). But the Oct-1 
and Oct-2 proteins display distinct transcriptional spec- 
ificities: Only Oct-2 readily activates a broad set of 
mRNA promoters (Tanaka and Herr 1990) and only 
Oct-1 is readily incorporated into the VP16-induced 
complex (Gerster and Roeder 1988). Oct-2 fails to form a 
complex with VP16 because the Oct-2 homeo domain 
differs from the Oct-1 homeo domain at 7 of 60 positions 
(Stem et al. 1989}. These amino acids are thought o be 
exposed to solvent when the homeo domain is bound to 
DNA and are thus available to interact with other pro- 
teins in the VP16-induced complex (Stem et al. 1989; see 
also Kissinger et al. 1990; Otting et al. 1990). 
Although the Oct-1 homeo domain is both necessary 
(Stem et al. 1989) and sufficient (Katan et al. 1990; 
Kristie and Sharp 1990) to direct formation of the VPl6- 
induced complex, it has not been established whether 
VP16 or HCF is the target of the homeo domain in these 
interactions. Here, by assaying VP16-induced complex 
formation in the absence of HCF, we show that VP16 can 
discriminate between the closely related Oct-1 and 
Oct-2 homeo domains. In addition, using VP16 mutants 
and synthetic peptides, we have localized the homeo do- 
main target region of VP16 to a position near its acidic 
activation domain. We present evidence suggesting that 
this target region constitutes a small independent VP16 
subdomain involved exclusively in homeo domain asso- 
ciation. 
Results 
In these studies wild-type and mutant VP16 proteins 
have been expressed in Escherichia coli as protein A fu- 
sions and purified from extracts with IgG--Sepharose 
beads. The carboxy-terminal 80-amino-acid acidic tran- 
scriptional activation domain of full-length VP 16, which 
is dispensable for VP16-induced complex formation 
(Greaves and O'Hare 1989; Kristie et al. 1989; Werstuck 
and Capone 1989b), was deleted from all of these con- 
structs. Wild-type Oct-1 POU domain, as well as a chi- 
meric Oct-1 POU domain carrying the Oct-2 homeo do- 
main (referred to as an Oct-l[Ho2] POU domain), have 
also been expressed in E. coli and were purified from 
extracts by DNA affinity chromatography {Kadonaga and 
Tjian 1986). Because HCF is normally required to ob- 
serve VPl6-induced complex formation, we sometimes 
refer to the VPl6-induced complex formed with VP16, 
the Oct-1 POU domain, and HCF under standard condi- 
tions (see below) as the HCF-dependent VP16-induced 
complex. Complexes formed with the Oct-1 POU do- 
main and VP16 in the absence of HCF are referred to as 
HCF-independent VP16-induced complexes. Below, 
wild-type VP16 and the two POU domain proteins have 
been used to establish that VP16 can specifically recog- 
nize the Oct-1 homeo domain in HCF-independent 
VP16-induced complexes; and mutant VP16 proteins, 
along with VP16-derived synthetic peptides, have been 
used to localize the homeo domain target region and to 
characterize its properties. 
HCF-independent recognition of the Oct-1 homeo 
domain by VP16 
Alone, VP16 does not interact efficiently with DNA 
(Marsden et al. 1987), and it has been thought that its 
association with specific cis-acting elements is entirely 
dependent on protein-protein teractions occurring in 
the VP16-induced complex. Recently, however, Kristie 
and Sharp (1990) showed that under some conditions 
VP 16-DNA complexes can be observed in mobility-shift 
assays and that the interaction of VP16 with DNA ap- 
pears to be stabilized by Oct-1. To establish that such 
HCF-independent Oct-l-VPl6 interactions are relevant 
to the well-characterized HCF-dependent VP16-induced 
complex, we designed a mobility-shift assay to test 
whether, in the absence of HCF, VP16 can distinguish 
between the closely related Oct-1 and Oct-2 homeo do- 
mains while they and VP16 bind specifically to DNA. In 
these assays, the requirement for HCF has been over- 
come by using high concentrations of VP16 and assay 
conditions that stabilize the complexes {see Materials 
and methods). 
In the mobility-shift assay shown in Figure 1A, in- 
creasing concentrations of VP 16 were incubated with an 
{OCTA + )TAATGARAT probe alone or along with either 
the Oct-1 POU domain or the chimeric Oct-l[Ho2] POU 
domain. When the Octo l POU domain (lane 2) or the 
Oct-l[Ho2] POU domain (lane 3) was incubated alone 
with the probe, the expected POU domain-DNA com- 
plexes formed. Addition of 10-fold more VP16 (10x, 0.5 
~g) than is normally used to form the HCF-dependent 
VP16-induced complex to the probe alone (lane 4) or to 
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Figure 1. HCF-independent VP16-induced complexes with Oct-1 and Oct-l[Ho2] POU domains. (A) Mobility-shift reactions with 
wild-type (OCTA § probe and increasing amounts of VP16 alone, or along with either the Oct-I or Oct-l[Ho2] POU 
domain. The identity of the POU domain and the quantity of VP16 used in each reaction are shown above the gel. Either no POU 
domain (-) ,  Oct-1 POU domain (1), or chimeric Oct-1 [Ho2] POU domain (2) was used in these reactions as indicated. About 50 ng of 
E. coli-expressed protein A-VP16 fusion protein is normally used to generate the HCF-dependent VPl6-induced complex. Here, either 
no VP 16 was added ( - )  or 500 ng (10 x ), 1.5 ~tg (30 x ), or 3 ~tg (60 x J of protein A-VP 16 fusion protein was included in the reaction. A 
short exposure of lanes 10-12 (10'-12') is shown at right and the identities of the different complexes are indicated at left. (B) 
Mobility-shift reactions with wild-type (OCTA+JTAATGARAT (lanes 1-6) and mutant GARAT - (lanes "7-12} probes. Reactions 
without ( - ) or with ( + ) Oct-1 POU domain, and without ( - ) or with either 1.5 ~tg (30 x) or 3 ~tg (60 x) of protein A-VP16 fusion protein 
are indicated. The complexes are identified at left; the sequences of the wild-type and mutant TAATGARAT motifs are shown below. 
the probe and either of the two POU domains (lanes 5 
and 6) resulted in no new complexes. Addition of 30-fold 
more VP16 (30x, 1.5 ~tg I by itself to the probe also re- 
sulted in no complex formation (lane 7); however, at this 
VP16 concentration, VP16 and the Oct-1 POU domain 
appeared to cooperate to produce a prominent new 
slowly migrating complex (lane 8), which we refer to as 
a POU domain-induced VP16-DNA complex (migrating 
between the POU/VP16 and VP16 labels). At the same 
time, the complex corresponding to the Oct-1 POU do- 
main itself was attenuated, and the remainder was het- 
erogeneously retarded in mobility (cf. lanes 5 and 8). The 
basis for this change in appearance is not fully under- 
stood (discussed below); however, formation of the upper 
POU domain-induced VP16-DNA complex is specific 
for the Oct-1 homeo domain, as no such complex formed 
when the Oct-l[Ho2] POU domain was used in an iden- 
tical reaction (cf. lanes 8 and 9). 
At a 60-fold higher than normal VP16 concentration 
(60x, 3 p.g), VP16 bound DNA on its own (lane 10), and 
the resulting complex migrated slightly faster than the 
POU domain-induced complex formed with 30x VP16 
(cf. lanes 8 and 10). Addition of the Oct-1 POU domain to 
this 60x VP16 binding reaction resulted in the apparent 
supershifting of the VP16-DNA complex (cf. lanes 10 
and 11, and lanes 10' and 11' in the shorter exposure). 
This supershifted complex probably contains the Oct-1 
POU domain, because when the POU domain was re- 
placed by just the Oct-1 homeo domain a smaller super- 
shift was observed (data not shown). Even at the 60• 
concentration VP16 continued to distinguish between 
the Oct-1 and Oct-2 homeo domains because substitu- 
tion of the Oct-l[Ho2] POU domain in an identical re- 
action eliminated formation of the POU domain-VP 16- 
DNA supershifted complex (lane 12). Thus, the seven 
Oct-2-specific amino acids within the homeo domain in- 
terfere with the ability of the Oct-1 POU domain and 
VP16 to interact simultaneously with DNA, suggesting 
that precise and intimate contacts form between these 
three complex components. 
Interestingly, while the POU domain-induced VP16- 
DNA complex (formed at 30• VP16, lane 8) and the 
POU domain-VP16-DNA complex {formed at 60x, 
VP16, lane 11) both migrated slower than the VP16-- 
DNA complex (formed at 60• lane 10), their mobil(ties 
were not identical {cf. upper complexes in lanes 8 and 
11). This observation suggests either that their compo- 
sitions differ or that their components have adopted if- 
ferent conformations that result in altered mobil(ties. 
Although the latter possibility cannot beruled out, we 
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favor the idea that the final position of the POU domain- 
induced VP16--DNA complex formed with 30x VP16 is 
the result of the decay during electrophoresis of an ini- 
tially formed ternary POU domain-VP 16-DNA complex 
into either a VP16-DNA or a POU domain-DNA com- 
plex. The resulting VP16-DNA complex will migrate 
faster than the stable POU domain-VP 16-DNA complex 
formed with 60x VP16, explaining their relative posi- 
tions in the gel. Additionally, if decay of the initially 
formed ternary complex takes place during an apprecia- 
ble fraction of the electrophoretic run, the final position 
of the smaller POU domain-DNA complex will vary, 
explaining its heterogeneous distribution in lane 8. In 
any case, the results in Figure 1A clearly show that HCF- 
independent VP16-induced complex formation requires 
Oct-1 homeo domain sequences. 
In addition to exhibiting specificity for the Oct-1 ho- 
meo domain, formation of the HCF-dependent VPl6- 
induced complex also requires GARAT-containing 
DNA sequences flanking the octamer motif in the 
(OCTA + )TAATGARAT element. Mutations within the 
GARAT subelement reduce VPl6-induced complex for- 
mation without affecting the interaction of Oct-1 itself 
with the probe (Gerster and Roeder 1988; O'Hare et al. 
1988; Kristie et al. 1989). Because VP16, but not HCF, 
has been shown to bind specifically to GARAT contain- 
ing DNA sequences (Kristie and Sharp 1990), these ob- 
servations suggest that VP16 interacts with the GARAT 
subelement within the HCF-dependent VP16-induced 
complex. If we are correct in concluding that within the 
HCF-independent VPl6-induced complexes shown in 
Figure 1A, VP16 specifically recognizes the Oct-1 homeo 
domain while it also interacts with DNA, then mutation 
of the GARAT subelement should disrupt selectively 
VP 16-DNA interactions while leaving the interaction of 
the Oct-1 POU domain with DNA unchanged. 
The experiment shown in Figure 1B, in which identi- 
cal reactions have been repeated with a wild-type 
{OCTA+)TAATGARAT probe (lanes 1--6) or a mutant 
probe (lanes 7-12) containing four point mutations 
within the GARAT subelement (Gerster and Roeder 
1988), shows that VP16-DNA interactions can be dis- 
rupted selectively. While binding of the Oct-1 POU do- 
main itself to the mutant probe was undiminished (cf. 
lanes 2 and 8), formation of the POU domain-induced 
VP16-DNA complex with 30x VP16 was not detectable 
(cf. lanes 4 and 10). At the 60x concentration level, how- 
ever, VP16 formed a small amount of complex with the 
mutant probe (lane 11; VP16-DNA complexes in lanes 
11 and 12 failed to form discrete bands and are visible 
only at the edges of the lanes). Unlike the VP16-DNA 
complex formed with the wild-type probe, however, for- 
mation of this VP16-DNA complex was not stimulated 
by the Oct-1 POU domain, nor was this complex super- 
shifted by the Oct-1 POU domain (cf. lanes 5 and 6 with 
11 and 12) These results suggest hat although it is able 
to bind to the mutant probe, VPl6 interacts aberrantly 
with it and, furthermore, that VP 16 recognizes the Oct-1 
homeo domain only when it can bind specifically to the 
GARAT subelement. Moreover, these results show that 
the previously observed specificities of the HCF-depen- 
dent VP16-induced complex, for the Oct-1 homeo do- 
main and GARAT-containing DNA sequences, can be 
fully accounted for by the specificities of VP16 in the 
absence of HCF, showing that HCF is not essential for 
normal Oct-l-VP16 interaction. The results of these ex- 
periments, therefore, serve to identify VP16 as the likely 
target of the Oct-1 homeo domain within the HCF-de- 
pendent VP16-induced complex. 
VP16 mutations affecting HCF, DNA, and Oct-I 
in teractions 
We then used VP 16 mutants to characterize the interac- 
tions of the protein with its three ligands: HCF, DNA, 
and Oct-1. The results of these assays have allowed us to 
localize the target of the Oct-1 homeo domain within 
VP16. The structures of the four mutant VP16 proteins 
are shown in Figure 2, which also summarizes the re- 
sults of these experiments. Previous mutagenesis studies 
(Ace et al. 1988; Werstuck and Capone 1989a, b; Greaves 
and O'Hare 1989, 1990) have identified two important 
regions for VP 16-induced complex formation; we refer to 
these as region I (amino acids 173-241) and region II 
(amino acids 317-403). We constructed two mutants, 
RI-A and RII-A, in which regions I and II are deleted in- 
dividually. We also assayed the activities of two previ- 
ously characterized 4-amino-acid insertion mutants, in9 
and inl4 (Ace et al. 1988), which we refer to here simply 
as RI-i and RII-i, respectively. These two mutations dis- 
rupt formation of the HCF-dependent VP16-induced 
complex; the RII-i mutant, however, can still participate 
in virion assembly, suggesting that its structure is not 
grossly altered (Ace et al. 1988). 
To study the effects of the four mutations on VP16- 
HCF interactions, we exploited the ability of VP16 to 
complex independently with HCF (Kristie and Sharp 
1990; Xiao and Capone 1990; this study) in an HCF mi- 
croprecipitation assay. HeLa cell nuclear extract was 
mixed with wild-type or mutant protein A-VP16 fusion 
protein, incubated for 30 rain at 30~ and added to IgG-- 
Sepharose beads, which bind the protein A moiety of the 
fusion proteins. The beads were washed, and proteins 
eluting with 1 M KC1 buffer (Xiao and Capone 1990) were 
monitored for HCF activity by assaying their abilities to 
promote formation of an HCF-dependent VP16-induced 
complex with Oct-1 POU domain and wild-type VP16 in 
a subsequent mobility-shift assay. In these reactions, the 
amount of VP16-induced complex formed in the mobil- 
ity-shift assay reflects the amount of HCF eluting from 
the beads. 
The first three panels of the mobility-shift assay 
shown in Figure 3 characterize this two-step HCF assay 
system. As shown in the first panel, the Oct-1 POU do- 
main readily bound the (OCTA § probe 
(lane 2), and as expected under these conditions, VP16 
did not bind the probe in the absence (lane 3) or presence 
(lane 4) of the Oct-1 POU domain. The second and third 
panels show that HCF activity was retained by the IgG- 
Sepharose beads in the presence (lanes 10-15) but not in 
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Figure 2. Structures and activities of 
wild-type and mutant protein A-VP16 fu- 
sion proteins. Wild-type VP 16 contains 490 
amino acids, with an 80-amino-acid car- 
boxy-terminal acidic transcriptional cti- 
vation domain (Activ.) that was deleted 
from the constructs used in this study. The 
wild-type protein lacking this domain is 
denoted "Wt." Two deletions were individ- 
ually made in wild-type VP16: either re- 
gion I, extending from amino acid 173 to 
241 inclusive (RI-A), or region II, extending 
from amino acid 317 to 403 inclusive (RII- 
A), was deleted. In addition, the previously 
described 4-amino-acid insertion muta- 
tions, in9 (after amino acid 177) and inl4 
(after amino acid 379) (Ace et al. 1988), 
were introduced individually within re- 
gions I and II and are referred to here as RI-i 
and RII-i, respectively. The amino acids in- 
serted by the in9 and inl4 mutations are 
indicated below their respective positions. 
The positions of sequences contained in the region I-derived peptide PEPI and the region II-derived peptide PEPII are shown below 
wild-type VP 16. PEPI contains amino acids 170-202 and overlaps in9, whereas PEPII contains amino acids 360--391 and overlaps in 14. 
Not shown is PEPII-i, which is identical to PEPII except hat it contains the 4-amino-acid inl4 insertion. The activities of each VP16 
construct are shown at right. Four activities were monitored in this study: formation of an HCF-dependent VP16-induced complex 
(VIC), HCF binding (HCF), DNA binding (DNA), and complex formation with the Oct-1 POU domain in the presence of DNA (POU). 
ND indicates that the POU-binding activity of the protein was not determined because the VP 16 mutant failed to interact with DNA. 
the absence {lanes 5-9) of wild-type protein A-VP16 fu- 
sion protein. The HeLa cell nuclear extract used in the 
precipitat ion reaction contains both endogenous Oct-1 
and HCF because it formed the expected Oct-1 complex 
wi th  the probe (lane 5), and it formed a VP16-induced 
complex {labeled VIC) when wild-type VP16 was added 
wi thout  {lane 6) or w i th  {lane 7) the Oct-1 POU domain. 
The eluate from a microprecipitat ion reaction performed 
wi thout  VP16 lacked endogenous Oct-1 (lane 8} and 
failed to form a VP16-induced complex when incubated 
with the Oct-1 POU domain and wild-type protein 
A-VP16 fusion protein {lane 9), showing that it does not 
contain HCF activity. When wild-type protein A-VP16 
fusion protein was included in the microprecipitat ion 
reaction the eluate again lacked endogenous Oct-1 (lane 
121, and it also failed to form a VP16-induced complex 
when either the Oct-1 POU domain (lane 13) or VP16 
{lane 14) was added individually. When the Oct-1 POU 
Figure 3. Microprecipitation assay for HCF 
binding by wild-type and mutant protein 
A-VP 16 fusion proteins monitored by mobility- 
shift assay. Association of HCF with wild-type 
and mutant VP16 was characterized in a HCF 
microprecipitation reaction, which was moni- 
tored in the mobility-shift assay shown here. 
The top line indicates whether no VP16 
l-VP161, wild-type protein A-VP16 fusion pro- 
tein [Wt), or one of the four VP16 mutants [RI-i, 
RI-A, RII-i, or RII-A) was added to the micropre- 
cipitation reaction. [Belowl The identity of the 
material assayed from the precipitation reac- 
tion, load (L) or elution {El), is indicated. Also 
shown are indications whether wild-type VP 16 
and/or Oct-1 POU domain was also added ( + or 
- ) to the mobility-shift reaction. The positions 
of the Oct-1 POU domain complex (POU), HeLa 
cell Oct-1 complex (Oct-l), and VP16-induced 
complex {VIC) are shown at le[t. All reactions 
were done in parallel, and the different panels 
are from a single gel. 
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domain and VP16 were added together, however, a VP 16- 
induced complex did form (lane 15), showing that HCF 
activity was retained on the beads in a VP16-dependent 
manner (cf. lanes 9 and 15). 
The effects of the four VP16 mutations on HCF recov- 
ery are characterized in the last four panels of Figure 3. 
As expected, all four of the mutants failed to form a 
VP16-induced complex with HeLa cell extract (cf. lanes 
16,19,22, and 25 with lane 10), and as before, the eluates 
from all four micro-precipitations were devoid of endog- 
enous Oct-1 (lanes 17,20,23,26). Three of the four mu- 
tant proteins, however, were still able to retain HCF on 
the IgG-Sepharose beads, although while the region II 
insertion mutant RII-i bound HCF at wild-type levels (cf. 
lanes 24 and 15), the region I mutants RI-i and RI-A re- 
tained HCF with reduced effectiveness (cf. lanes 18 and 
21 with 15). The fourth mutant, RII-A, was unable to 
retain HCF in this assay (lane 27). These results, which 
are summarized in Figure 2, show that while region I was 
not required for HCF retention, it may still be involved 
in HCF binding as mutations within this region de- 
creased the ability of VP16 to associate with HCF. In 
contrast with these results, deletion of region II reduced 
HCF retention to undetectable vels in the assay, sug- 
gesting that region II of VP 16 is required for HCF binding 
and offering an explanation for why the RII-A protein 
failed to form an HCF-dependent VP16-induced com- 
plex. Because the other three mutant proteins continued 
to interact with HCF, however, these results also suggest 
that other interactions required for VP16-induced com- 
plex formation have been affected by these mutations. 
To test this hypothesis, we then assayed the abilities of 
the four mutant proteins to interact with DNA and the 
Oct-1 POU domain in the absence of HCF. 
As shown in Figure 4, the DNA-binding capacities of 
wild-type and mutant VP16 proteins were tested in the 
absence or presence of the Oct-1 POU domain, at both 
30x and 60x VP16 concentrations. As expected, wild- 
type VP16 cooperated with the Oct-1 POU domain to 
bind the probe at the 30x VP16 concentration (lane 4), 
and the VP16-DNA complex formed at 60x VP16 con- 
centration (lane 5) was supershifted by the Oct-1 POU 
domain (lane 6). In contrast, the region I insertion mu- 
tant RI-i (lanes 7-10), and the two VP16 deletion mu- 
tants RI-A (lanes 11-14) and RII-A (lanes 19-22) did not 
bind DNA in the absence or presence of the Oct-I POU 
domain. The region II insertion mutant RII-i, however, 
bound DNA on its own as well as, or better than, wild- 
type VP16 (cf. lanes 3 and 15). Surprisingly, however, it 
failed to interact productively with the Oct-1 POU do- 
main at both the 30• and 60x concentrations. Addition 
of the Oct-1 POU domain to a reaction containing a 30 • 
concentration of RII-i protein resulted in a reduction of 
the amount of VP16-DNA complex, rather than in an 
increase (cf. lanes 15 and 16 with lanes 3 and 4), suggest- 
ing that rather than cooperating with the POU domain, 
the RII-i protein and the POU domain compete for the 
DNA probe. Competitive behavior was also observed at 
the 60 x concentration, as the RII-i-DNA complex failed 
to be supershifted by the Oct-1 POU domain (cf. lanes 6 
Figure 4. HCF-independent VPl6-induced complexes with 
Oct-1 POU domain and wild-type or mutant protein A-VP16 
fusion proteins. Mobility-shift reactions are shown with the 
(OCTA*)TAATGARAT probe and either wild-type (Wt) or mu- 
tant (Rid, RI-A, RII-i, or RII-A) VP16 proteins and the Oct-1 POU 
domain. Either no VP16 ( - ], or 1.5 ~g (30x) or 3 v-g (60x) of the 
protein A-VP16 fusion proteins were added, and reactions re- 
ceiving Oct-1 POU domain are indicated {+ and - ). The posi- 
tions of the different complexes are shown at left; the different 
panels are from a single gel. 
and 18), and instead, the RII-i protein appeared to ex- 
clude the POU domain from binding the probe (cf. the 
POU domain complexes in lanes 16 and 18). These re- 
sults suggest hat the VP16 region interrupted by the 
RII-i mutation is involved intimately in POU domain 
association, as it abolishes the strongly cooperative 
Oct-1 POU domain-VP16 interaction, and reverses it, so 
that the two proteins compete for the DNA probe. 
Interestingly, as summarized in Figure 2, the effects of 
the RII-i insertion mutation are highly specific. This is 
because while this mutation dramatically affects the in- 
teraction of VP16 with the Oct-1 POU domain, it leaves 
the DNA- and HCF-binding activities of VP16 virtually 
unchanged. It is l ikely that the effects of the RII-i muta- 
tion on POU domain association are a consequence of its 
failure to interact with the Oct-1 homeo domain, be- 
cause in reactions in which the Oct-1 POU domain was 
replaced by the Oct-1 homeo domain, the RII-i protein 
failed to interact productively with the homeo domain 
itself (data not shown). Along with the effects of the RII-i 
mutation, the inabil ity of the Oct-2 borneo domain to 
interact with VP16 shows that subtle alterations i  the 
interacting surfaces of either the Oct-1 homeo domain or 
VP16 can have strong effects on complex formation be- 
tween these two proteins, without affecting other con- 
tacts in the VP16-induced complex. 
VP16-derived peptides form complexes with DNA 
and the POU domain 
The observation that the RII-i mutation only affects the 
ability of VP16 to associate with the Oct-1 POU domain 
suggests that VP16 contains an independent subdomain 
involved exclusively in this activity. To examine this 
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possibility, we have used synthetic peptides derived 
from regions I and II to test the ability of small segments 
of VP16 to form complexes with DNA and the Oct-1 
POU domain in mobility-shift assays. A synthetic pep- 
tide has been used previously to inhibit HCF-dependent 
VP16-induced complex formation (Haigh et al. 19901, 
probably by competing with VP16 for either Oct-1 or 
HCF. The region I (PEPI)- and region II (PEPII)-based pep- 
tides extend from amino acids 170 to 202 and 360 to 391, 
respectively, and as shown in Figure 2, they encompass 
the segments of VP16 altered by the RI-i and RII-i inser- 
tion mutations. To characterize the specificity of peptide 
complexes, the activities of a region II peptide containing 
the 4-amino-acid insertion of the RII-i VP16 mutation 
(PEPII-i) and of an unrelated peptide containing adenovi- 
rus Ela protein sequences were also tested. 
As shown in Figure 5A, incubation of 1 ~g of PEPI with 
the (OCTA +)TAATGARAT probe resulted in retention 
of much of the probe at the top of the gel, as well as in 
the formation of poorly defined PEPI-DNA complexes 
(lane 1). Addition of increasing amounts of poly[d(I-C)] to 
the reaction resulted in a decrease in probe-containing 
PEPI aggregates (lanes 2,3) and in the partial resolution of 
a PEPI-DNA complex at an intermediate poly[d(I-C)] 
concentration llane 2). These results show that PEPI 
binds DNA on its own and that it can produce large 
probe-containing aggregates. Both of these characteris- 
tics are similar to those of intact VP 16, which exhibits a 
similar sensitivity to poly[d(I-C)] in its interactions with 
DNA and also produces poly[d(I-C)]-sensitive probe-con- 
taining aggregates (data not shown). PEPI-DNA interac- 
tions are comparatively nonspecific, however, because 
unlike intact VP16, PEPI bound a probe of unrelated se- 
quence with similar affinity (data not shown). Interest- 
ingly, the DNA-binding activity of PEPI is consistent 
with the apparent involvement of region I of VP 16 in this 
activity (summarized in Fig. 2). 
The characteristics of PEPI contrast with those of the 
Ela-derived peptide, PEPII, and PEPII-i shown in Figure 
5B. Here, increasing amounts (1.2, 3.8, or 12 vLg) of each 
peptide have been incubated with the DNA probe, either 
alone or together with the Oct-1 POU domain. None of 
these peptides bound the DNA probe effectively by 
themselves (lanes 2-10), although in some assays PEPII 
exhibited a low affinity for DNA (data not shown). How- 
ever, unlike the Ela peptide (lanes 12-14), PEPII formed 
a discrete supershift with the Oct-1 POU domain-DNA 
complex (lanes 15-17). Formation of only a single super- 
shifted complex suggests that the interaction of PEPII 
with the Oct- 1 POU domain is specific, a hypothesis that 
is underscored by the reduced ability {-5- to 10-fold) of 
the mutant peptide, PEPII-i, to form the analogous com- 
plex (lanes 18-20). From these experiments we conclude 
that the VP16 region implicated in homeo domain rec- 
ognition can also independently form a complex with 
the POU domain. The activity of PEPII is likely relevant 
to VP16 function because, as in the full-length protein, 
the 4-amino-acid insertion mutation interferes with 
POU-domain association. These results therefore sup- 
port the idea that this VP 16 region contains an indepen- 
dent homeo domain recognition subdomain. 
Discuss ion  
By showing that VP16 can recognize the Oct-1 homeo 
domain in the absence of HCF, we have been able to 
identify VP16 as the likely target of the Oct-1 homeo 
domain in a protein-protein interaction that regulates 
transcription. The properties of the VP16 mutants and 
synthetic peptides that we have described suggest hat 
the region of VP16 that interacts with the Oct-1 homeo 
domain comprises an independent subdomain. The ex- 
istence of such a subdomain is consistent with the mod- 
ular organization of many transcription factors and sug- 
gests that the homeo domain recognition subdomain can 
be added to a growing list of transcription factor domains 
Figure 5. Complexes formed with VP16- 
derived peptides PEPI, PEPII, and PEPII-i. 
(A} Mobility-shift reactions with the 
(OCTA+)TAATGARAT probe and 1 ~g of 
PEPI in reactions containing 0.35 ~g (lane 
11, 0.55 ~g (lane 21, or 0.75 Ixg (lane 31 of 
poly[d(I-C}]. The positions of the heteroge- 
neous PEPI-DNA complexes are indicated 
at left. (B} Mobility-shift reactions are 
shown with the {OCTA*}TAATGARAT 
probe and 1 ( .2 wg), 3 (3.8 ~g), or 10 units 
(12 ~gl of the Ela, PEPII, or PEPII-i peptides. 
Reactions were repeated without and with 
added Oct-1 POU domain as indicated. The 
positions of the Oct-1 POU domain, PEPII- 
POU domain, and PEPII-i-POU domain 
complexes are shown at right. The mobility 
of the PEPII-i-POU domain complex is 
slightly decreased compared with that of the 
PEPII-POU domain complex, probably be- 
cause of the increased size of PEPII-i. 
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that includes various DNA-binding and transcriptional 
activation domains, and protein dimerization motifs. 
Like the interactions of the yeast c~2 transcription factor 
with the al and GRM/MCM1 proteins (Goutte and 
Johnson 1988; Keleher et al. 19881, the characteristics of 
the VP16-induced complex show how the regulatory ac- 
tivity of a homeo domain-containing transcription factor 
can be altered by protein-protein teractions. But un- 
like the yeast system, in which regions flanking the ho- 
meo domain are responsible for these interactions, the 
Oct-1 homeo domain itself directs formation of protein- 
protein contacts in the VP16-induced complex. 
The VP16 region implicated in homeo domain recog- 
nition by the RII-i mutation appears to contain an inde- 
pendent subdomain because the 33-amino-acid peptide 
derived from it, PEPII, forms a complex with the POU 
domain. The specificity of PEPII-POU domain interac- 
tion is supported by the reduced affinity of the mutant 
peptide PEPII-i for the POU domain. However, the inter- 
actions of PEPII and VP16 with the Oct-1 POU domain 
differ in two important respects. First, unlike full-length 
VP16, PEPII fails to discriminate between the Oct-1 and 
Oct-2 homeo domains [data not shown). Second, the ef- 
fects of the 4-amino-acid insertion mutation are qualita- 
tively different in PEPII and VP16: Although PEPII-i in- 
teracts with the POU domain-DNA complex with re- 
duced effectiveness, when VP16 carries the RII-i 
mutation it competes with the POU domain for the 
DNA probe (see Fig. 4). Both of these differences are in- 
dicative of a relaxed specificity in PEPII interactions, 
suggesting that other VP16 regions may be directly in- 
volved in Oct-1 association. These differences could also 
be a consequence, however, of the different environ- 
ments that these amino acids are subject o within PEPII 
and VP 16. In VP 16, interactions with the rest of the pro- 
tein likely stabilize the conformation of the amino acids 
in this region, perhaps resulting in increased specificity 
for complex formation. In addition, the orientation of the 
PEPII region in VP16 may be constrained by the interac- 
tion of VP16 with DNA, which likely fixes the relative 
positions of the interacting regions of VP16 and the 
Oct-1 homeo domain. 
If VP16 contains a subdomain that recognizes the 
Oct-1 homeo domain in mobility-shift experiments, why 
does it fail to interact with Oct-1 in VP16 affinity chro- 
matography experiments (Kristie and Sharp 1990; Xiao 
and Capone 1990 this study)? One difference between 
these two assays is that a specific DNA-binding site is 
present only in the mobility-shift reaction, suggesting 
that Oct-l-VP16 interactions are DNA binding site de- 
pendent. Perhaps in the absence of DNA, the protein- 
protein contacts formed between the Oct-1 homeo do- 
main and VP16 are not sufficiently strong to stably bind 
Oct-1. In this case, the mutual interaction of Oct-1 and 
VP16 with DNA would serve to stabilize their associa- 
tion. Alternatively, DNA binding by either Oct-1 or 
VP16 may alter their conformation so as to increase the 
stability of the protein-protein contacts. Consistent 
with this hypothesis, comparison of the structures of 
free and DNA-bound Antennapedia homeo domains de- 
duced by nuclear magnetic resonance (NMR1 has shown 
that amino acids in helix 2, which in Oct-1 are involved 
in VP16-induced complex formation (Stern et al. 1989), 
have different conformations (Otting et al. 1990}. 
The properties of the four VP16 mutants assayed here 
also allow us to begin to understand the functional do- 
main structure of VP16. Mutations within region I of 
VP16 strongly diminish the ability of the protein to in- 
teract with DNA in the absence or presence of the Oct-1 
POU domain, suggesting that region I is required for 
DNA binding and that it could be involved directly in 
this activity. Consistent with this hypothesis, region I 
contains the most basic region of the VP16 polypeptide, 
and a synthetic peptide containing amino acids 170-202 
of VP16 (PEPI) interacts avidly but nonspecifically with 
DNA. Mutations within region I also affect HCF associ- 
ation but not as dramatically as deletion of region II does, 
suggesting that HCF interacts primarily with region II of 
VP16. Deletion of region II, however, also strongly di- 
minishes VP16-DNA interactions; therefore, it is un- 
clear whether this deletion generally inactivates VP 16 by 
unfolding its native structure. Further studies will be 
required to clarify the functional roles of these different 
VP 16 regions. 
As shown in Figure 6 the homeo domain recognition 
subdomain, which we have defined as approximately co- 
incident with PEPII, lies near the acidic activation do- 
main of VP16. The PEPII region may contain a 12-amino- 
acid amphipathic oL-helix (Lim 1974a, b) which could 
form as indicated in Figure 6. The RII-i insertion, which 
selectively disrupts the interaction of VP16 with the 
Oct-1 POU domain, lies within this putative helix, as do 
several point and truncation mutations that negatively 
affect HCF-dependent VP16-induced complex assembly 
(Greaves and O'Hare 1990). Interestingly, the VP16 ana- 
log (ORF10 protein) of the HSV-related varicella-zoster 
virus (VZV) lacks both a region analogous to positions 
378-389 of VP16 and a carboxy-terminal acidic domain 
(Dalrymple t al. 1985). The results of the present studies 
suggest that a deletion in the 378-389 region should ren- 
der the protein unable to interact with Oct-l, while the 
absence of a carboxy-terminal acidic region in the ORF 10 
protein suggests that it will not activate transcription. 
Consistent with these expectations, the ORFIO protein 
fails to form a multiprotein-DNA complex analogous to 
the VP16-induced complex and also fails to stimulate 
VZV IE gene transcription (McKee et al. 1990). The cor- 
related presence and absence of homeo domain recogni- 
tion and transcriptional ctivation domains, in VP16 and 
the ORF10 protein, respectively, suggest hat these two 
domains have been acquired together by VP16 during 
evolution. 
It remains to be determined to what extent protein- 
protein interactions with homeo domains contribute to 
cellular transcriptional regulation, particularly during 
development. Because the homeo domain, which consti- 
tutes a largely independent DNA recognition domain, 
has been so highly conserved, it is tempting to speculate 
that the region of VP16 involved in homeo domain rec- 
ognition, which also appears to constitute an indepen- 
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Figure 6. Diagram of VP16 showing the homeo domain recog- 
nition region. The positions of region I (RI; amino acids 173- 
241), region II (RII; amino acids 317-403), and the carboxy-ter- 
minal acidic activation domain (Act.) are indicated. The RI-i 
(in9, at amino acid 177) and RII-i {inl4, at amino acid 379} in- 
sertion mutations overlap sequences contained in the peptides 
PEPI and PEPII, respectively. The sequence of PEPII is shown in 
the middle. Analysis of this sequence according to the algo- 
rithms of Lim {1974a, b; S. Stern and J. Stem, unpubl.), suggests 
that it is compatible with the formation of an amphipathic a-he- 
lix extending from amino acid 370 to 381. As shown beneath the 
sequence, amino acids 373-381 form an X fragment (Lim 
1974a,b; indicated by XXXXX), which is composed of a hydro- 
phobic 1-S pair (Y372-I376) linked with a hydrophobic 1-4-5 
triplet (I376-L380-L381). The X fragment can be extended on its 
amino-terminal side to K370 (indicated by zzz), which forms a 
1-4 electrostatic pair with Y373. The position of the RII-i in- 
sertion within the putative a-helix s shown by the vertical 
arrow. 
dent domain, has l ikewise been conserved and distrib- 
uted among a family of cellular transcript ion factors. 
Such factors could be considered to be cellular VP 16 an- 
alogs. Consistent  wi th  the existence of such proteins, 
the HCF act ivity required for efficient VP16-induced 
complex assembly has been detected in insect (SF91 cells 
(Kristie et al. 1989) and in Drosophila embryos (S. Stem, 
unpubl.). If cellular VP16 analogs do exist they may or 
may not contain potent transcript ional activation do- 
mains. In either case, l ike VP16, they could funct ion to 
increase the specif icity of their target factors by simul- 
taneously interact ing wi th  homeo domains and the 
DNA sequences f lanking homeo domain recognit ion 
sites. Such interact ions could help to explain how ho- 
meo domain proteins, which exhibit  overlapping DNA 
specificities in vitro, give rise to highly specific effects in 
animals. 
Mater ia ls  and methods  
VP16 and POU-domain expression constructs 
VP16 expression constructs were derived from a SalI fragment 
encoding amino acids 5--411 of VP16. This SalI fragment, as 
well as the parental expression vector pRIT2T (Pharmacia), 
were isolated from the plasmid pRIT65 {Werstuck and Capone 
1989b), which was a kind gift from I. Capone. The 'wild-type' 
construct containing VP16 residues 5-411 was produced by li- 
gating the VP16-encoding SalI fragment into pRIT2T. Mutant 
VP16 constructs were produced by oligonucleotide-directed 
mutagenesis of the VP 16 Sali fragment, which was inserted into 
the SalI site of pUC 119. Primers AACTTCTGCGCAAGGATC- 
CGCGCACTGTACCGGTACCT, TATCGAACCGTGTTGG- 
CCGCGTACGCCGAG, TCTACCATCGAGGGAGCGGATC- 
CAAGACTGCTCGATCTCCC, and GGAGGAGCCAGGG- 
GCGGGACACACGCGC were used for the RI-i, RI-A, RII-i, and 
RII-A mutations, respectively, and the mutations were verified 
by restriction site mapping and DNA sequencing. The mutant 
SalI fragments were then transferred back into pRIT2T. 
DNA fragments encoding the Oct-1 and Oct-l[Ho2] POU do- 
mains were generated by polymerase chain reaction (PCR) am- 
plification using plasmids pBSoct-1 + (Sturm et al. 1988) for the 
Oct-1 POU domain and pBSaoct-l(2Jl(N)2(3}l {Stem et al. 1989) 
for the Oct-l[Ho2] POU domain. Primers GATCATAT- 
GAGCTTGGAGGAGCCC (5')and ACTGGATCCTCAGTT- 
GATTCTITITTC {3'/were used to amplify the POU domain 
sequences. NdeI and BamHI sites in the primers, as well as an 
in-frame stop codon in the 3' primer are underlined. The ATG 
of the NdeI site at the 5' end of the fragments i  in-frame with 
the coding sequences. The PCR fragments were cut with NdeI 
and BamHI, and ligated between the NdeI and BamHI sites of 
the T7 expression vector pET3b (Studier et al. 1990). 
VP16 and POU-domain expression and puri[ication 
Wild-type and mutant VP16 proteins were produced as fusions 
with staphylococcal protein A in pRIT2T. Expression con- 
structs were transformed into E. coli strain N4830 [Pharmacia), 
which harbors a thermolabile x repressor protein. Half-liter cul- 
tures were grown to  A6o  o = 0.5 at 30~ induced by temperature 
shift to 42~ by addition of an equal volume of LB media at 
56~ and expression was llowed to continue for 1-2 hr at 42~ 
The ceils were then pelleted and washed, and the pellets were 
frozen. After thawing on ice for 15 rain, the cell pellet from 1 
liter of induced culture was resuspended in 50 ml of 50 mM 
Tris-HC1 (pH 7.61, 250 mM NaCI, 10 mM EDTA, 13% sucrose, 
0.1% NP-40, and 250 o.g/ml of lysozyme and incubated on ice 
for 30 min. Cell debris was pelleted at 100,000g for 1.5 hr, and 
the supematant was added to 2 ml of IgG-Sepharose {Pharma- 
cia}, which had been equilibrated with TST buffer [50 mM Tris- 
HCI (pH 7.61, 150 mM NaC1, 0.05% Tween 20J as recommended 
by the manufacturer. After mixing end over end for 1 hr at 4~ 
the beads were pelleted with a low-speed spin, and 90% of the 
supematant was removed. The beads were resuspended in the 
remaining supernatant and transferred to a S-ml Dispo-column 
(Bio-Radl. After washing with 20 ml of TST buffer, followed by 
4 ml of 5 mM NHaAc (pH 5.01, proteins were eluted with 0.5 M 
HAc IpH 3.6J and desalted over a PD10 column iPharmacia) into 
50 mM Tris-HC1 {pH 7.61, 100 mM NaC1, 1 mM EDTA, 1 mM 
DTT, and 10% glycerol buffer. Expression levels and purity 
were monitored by SDS-PAGE, followed by silver staining, and 
by Western blotting with radiolabeled IgG. Typically, -2  mg of 
fusion protein per liter of induced culture was obtained for the 
wild-type and RII-i VP16 proteins, whereas -10-fold less was 
obtained for the RI-i, RI-A, and RII-A mutants. Proteins ex- 
pressed at lower levels were concentrated to wild-type protein 
levels with Centricon concentrators IAmicon). The final nor- 
malized concentrations of the wild-type and mutant proteins 
were verified by Western blotting. 
The Oct-1 and Oct-l[Ho2] POU domains were expressed in 
BL211DE3) cells. Half-liter cultures were grown at 37~ to 
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A6o o = 0.8, transferred to30~ and induced with 0.4 mM IPTG. 
After several hours, the cells were pelleted and washed, and the 
cell pellets were frozen. Pellets were resuspended in 50 ml of 50 
mM Tris-HCl (pH 7.6), 100 mM NaC1, 10 mM EDTA, 1 mM DTT, 
0.1% NP-40, 10% glycerol, and 250 ~g/ml of lysozyme and 
incubated on ice for 30 min. Cell debris was pelleted at 100,000g 
for 1 hr, and soluble POU-domain proteins were purified by 
DNA affinity chromatography (Kadonaga nd Tjian 1986). Pro- 
teins were eluted with 50 mM Tris-HC1 (pH 7.6), 1 M NaC1, 1 
mM EDTA, 1 mM DTT, and 10% glycerol buffer. 
Mobility-shift assay for HCF-independen t VP16-induced 
complexes 
Protein-DNA binding reactions were p rformed in 12.5-~.1 re- 
actions containing 20 mM K-HEPES (pH 7.9), 60 mM KC1, 2 mM 
EDTA, 0.5 mM DTT, 0.03% NP-40, 2% Ficoll 400, 0.1 mg/ml of 
BSA, and 0.35 p.g of unsonicated poly[d(I-C)] (Pharmacia). Ap- 
proximately 0.5 ng of POU proteins and the indicated amounts 
of protein A-VP16 fusion proteins were incubated with the 
probe for 30 min at 30~ and half the reaction (6 v.ll was care- 
fully layered onto the bottom of the well of a 6%, 19 : 1 acry- 
lamide/bis-acrylamide, 0.25x TBE gel, which was run at 12 
V/cm for -3  hr at room temperature. Probes, containing wild- 
type and mutant TAATGARAT elements derived from the HSV 
ICPO promoter (Gerster and Roeder 1988) inserted into the 
pUC119 polylinker, were 3' end-labeled with Klenow fragment 
and ~-a2P-labeled dNTPs. Formation and/or observation of 
HCF-independent VP16-induced complexes appears to depend 
on the characteristics of the mobility-shift gel, as these com- 
plexes have not been observed with 4% 39 : 1 acrylamide/bis- 
acrylamide gels. 
HCF microprecipitation assay 
Fifty microliters of 7 mg/ml HeLa cell nuclear extract in buffer 
D (Dignam et al. 1983) and 1 ~1 of -500 p.g/ml of wild-type or 
mutant VP16 protein were combined and incubated for 30 rain 
at 30~ Reactions were then centrifuged at 4~ for 10 min at 
16,000g, and the supematants were added to 20 gl of IgG-Seph- 
arose beads (Pharmacia] that had been equilibrated in TST 
buffer. The beads were mixed end over end for 30 min, pelleted, 
and washed twice with 200 ~1 of TST. The beads were then 
washed three times with 50 ~1 of high-salt buffer ]50 mM Tris- 
HC1 (pH 7.6), 1 M KC1, 1 mM EDTA, 1 mM DTT, and 10% 
glycerol]. Because of dilution by the remaining wash buffer, the 
first two high-salt washes produced intermediate salt levels that 
did not selectively elute VP16-associated HCF. The eluate from 
the third high-salt wash, however, was devoid of nonspecifically 
retained HCF and was used to characterize VP16-specific reten- 
tion of HCF activity in subsequent mobility-shift reactions con- 
taining 0.1-0.5 ng of Oct-I POU domain and 50 ng of wild-type 
protein A-VP16 fusion protein. In some experiments, asin the 
one shown in Figure 3, 1 ~g of the region I peptide, PEPI, was 
added to the mobility-shift reaction because it enhances forma- 
tion of the VP16-induced complex. The basis for this effect is 
not known, but the same qualitative results have been obtained 
with and without he addition of PEPI. Mobility-shift reactions 
were carried out essentially as described in Stem et al. (1989) 
except hat the final salt concentration was 100 mM instead of 
60 mM. Complexes were resolved with 4%, 39 : 1 acrylamide/ 
bis-acrylamide g ls in 0.25 x TBE. 
Synthetic Peptides 
Peptides PEPI (CTVLANFCSALYRTLRASVRQLHRQAHMR- 
GRDRD), PEPII (CREHAYSRARTKNNYGSTIEGLLDLPD- 
DDAPEE), PEPII-i (CREHAYSRARTKNNYGSTIEGADPRLLD- 
LPDDDAPEE} (the RII-i insertion is underlined), and Ela 
(HFEPPTVHEVYDVQPQVIEVTSHDAGFPPS), which was the 
kind gift of Nick Dyson and Ed Harlow, were synthesized on an 
Applied Biosystems 430A peptide synthesizer using N-~-Boc 
amino acid derivatives. In addition to VP 16 sequences, peptides 
PEPI, PEPII, and PEPII-i contain amino-terminal cysteines. The 
peptides were removed from the resin using liquid HF, precip- 
itated with ethyl ether, and purified by two rounds of reverse- 
phase high performance liquid chromatography (HPLC). The 
structures of the final products were confirmed by plasma de- 
sorption mass spectrometry and analytical HPLC. Lyophilized 
peptides were suspended in water, and final peptide concen- 
trations were determined byamino acid analysis. The activities 
of the peptides were characterized in mobility-shift assays using 
conditions described above for HCF-independent VP16-induced 
complexes. 
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